What is it about?
The aim of this study was to investigate the feasibility of employing S-carboxymethyl-l-cysteine as a treatment of chronic obstructive pulmonary disease in dogs. To this end the pharmacokinetic parameters of orally administered S-carboxymethyl-l-cysteine were determined in the dog, cow and sheep. Six healthy beagle dogs, six endogenous Greek sheep and four Holstein Fresian calves were orally dosed with 10 mg/kg body weight of S-carboxymethyl-l-cysteine. No significant differences in Tmax and T1/2 were reported between the species. However, significantly higher AUC(0–last), 21.56±6.67ghml−1 and AUC(0–∞), 21.63±6.68ghml−1 were seen in the dogs compared to the sheep and calves. The calculated VD was significantly higher in the sheep (10.4±2.7Lkg−1) and the calves (3.8±0.7Lkg−1) compared to the dogs (1.0±0.6Lkg−1). The rank order of increasing CL was sheep (3.4±2.7Lh−1 kg−1) > calves (2.7±0.4Lh−1 kg−1) > dogs (0.5±0.2Lh−1 kg−1). The result for the dogs was significantly lower that the calculated CL for the sheep and calves. All these results indicate that the oral administration of S-carboxymethyl-l-cysteine may be useful during the therapeutic management of chronic obstructive pulmonary disease in dogs.
Photo by Hush Naidoo on Unsplash
Why is it important?
The fists reports of the pharmacokinetics of S-carboxymethyl-l-cysteine in dogs, sheep and cows.
Read the Original
This page is a summary of: The pharmacokinetics of orally administered S-carboxymethyl-l-cysteine in the dog, calf and sheep, European Journal of Pharmaceutical Sciences, February 2010, Elsevier, DOI: 10.1016/j.ejps.2009.12.003.
You can read the full text:
Be the first to contribute to this page